Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study

John W Devlin1,2*, Yoanna Skrobik3, Richard R Riker4, Eric Hinderleider1, Russel J Roberts5, Jeffrey J Fong6, Robin Ruthazer7, Nicholas S Hill2 and Erik Garpestad2

Abstract

Introduction: We hypothesized that delirium symptoms may respond differently to antipsychotic therapy. The purpose of this paper was to retrospectively compare duration and time to first resolution of individual delirium symptoms from the database of a randomized, double-blind, placebo-controlled study comparing quetiapine (Q) or placebo (P), both with haloperidol rescue, for critically ill patients with delirium.

Methods: Data for 10 delirium symptoms from the eight-domain, intensive care delirium screening checklist (ICDSC) previously collected every 12 hours were extracted for 29 study patients. Data between the Q and P groups were compared using a cut-off \( P \leq 0.10 \) for this exploratory study.

Results: Baseline ICDSC scores (5 (4 to 7) (Q) vs 5 (4 to 6)) (median, interquartile range (IQR)) and % of patients with each ICDSC symptom were similar in the two groups (all \( P > 0.10 \)). Among patients with the delirium symptom at baseline, use of Q may lead to a shorter time (days) to first resolution of symptom fluctuation (4 (Q) vs. 14, \( P = 0.004 \)), inattention (3 vs. 8, \( P = .10 \)) and disorientation (2 vs. 10, \( P = 0.10 \)) but a longer time to first resolution of agitation (3 vs. 1, \( P = 0.04 \)) and hyperactivity (5 vs. 1, \( P = 0.07 \)). Among all patients, Q-treated patients tended to spend a smaller percent of time with inattention (47 (0 to 67) vs. 78 (43 to 100), \( P = 0.025 \)), hallucinations (0 (0 to 17) vs. 28 (0 to 43), \( P = 0.10 \)) and symptom fluctuation (47 (0 to 67) vs. 89 (33 to 00), \( P = 0.04 \)) and there was a trend for Q-treated patients to spend a greater percent of time at an appropriate level of consciousness (26% (13 to 63%) vs. 14% (0 to 33%), \( P = 0.17 \)).

Conclusions: Our exploratory analysis suggests that quetiapine may resolve several intensive care unit (ICU) delirium symptoms faster than the placebo. Individual symptom resolution appears to differ in association with the pharmacologic intervention (that is, P vs Q, both with as needed haloperidol). Future studies evaluating antipsychotics in ICU patients with delirium should measure duration and resolution of individual delirium symptoms and their relation to long-term outcomes.

Introduction

Delirium, characterized by acute disturbances of consciousness and cognition that develop over a short time in the context of an acute medical condition, occurs in up to 50% of intensive care unit (ICU) patients [1,2]. Critically ill patients who develop delirium have a higher mortality, a longer duration of mechanical ventilation and may develop long-term cognitive abnormalities [3-7]. The Intensive Care Delirium Screening Checklist (ICDSC) is an eight-domain instrument that was specifically developed and validated for screening delirium in ICU patients [8]. It has been shown to identify delirium as well as psychiatrists using Diagnostic and Statistical Method (DSM) IV criteria, to be highly reliable, to...
Materials and methods

Data for this IRB-approved, retrospective, post-hoc analysis is derived from a three-center, double-blind, placebo-controlled study that evaluated the efficacy and safety of quetiapine in adult ICU patients with delirium (ICDSC ≥4), who had an order for as-needed haloperidol and were tolerating enteral nutrition [20]. While informed consent was obtained from all subjects in the original study, the IRB did not require subjects to provide consent for their data to be used in this secondary analysis given its post-hoc nature. During the study period 258 ICU patients were screened and 222 were excluded. The exclusion criteria for this study were extensive and included conditions that could mimic delirium or place patients at increased risk for quetiapine-related adverse effects. Delirium assessments were conducted every 8 to 12 hours by trained bedside nurses using the ICDSC. All patients were managed with the same as-needed intravenous haloperidol protocol. Therapy (that is, quetiapine or a matching placebo) was administered orally or via a nasogastric/enteral tube and initiated at a dose of 50 mg every 12 hours. Therapy was titrated upwards on a daily basis by increments of 50 mg every 12 hours to a maximum dose of 200 mg every 12 hours if the subject received at least one dose of as-needed haloperidol in the previous 24 hours. The study drug was continued until one of the following occurred: 1) the subject was deemed by the attending intensivist (based on their clinical judgment) to no longer demonstrate signs of delirium and, therefore, to no longer require therapy with a scheduled antipsychotic; 2) 10 days of therapy had elapsed; 3) ICU discharge occurred; or 4) an adverse event potentially attributable to the study drug occurred.

The ICDSC data were extracted from the study database for subjects with more than half of the every-12-hour ICDSC assessments completed in full during blinded study drug administration. If more than one ICDSC score was available for each 12-hour study period, the ICDSC with the highest score was used. While the ICDSC evaluates eight different domains associated with delirium, it actually evaluates 10 different delirium symptoms [8]. Data from ICDSC domain #1 (level of consciousness) evaluates both agitation and decreased level of consciousness and ICDSC domain #5 (motor activity) evaluates both hyperactivity and hypoactivity. Therefore, these four symptoms for domains #1 and #5 were collected with the single symptoms from the other six domains, resulting in 10 different symptoms of delirium being evaluated.

The prevalence of each delirium symptom present at the study baseline was compared between the quetiapine and placebo groups using Pearson’s chi-square tests. Among subsets of patients with each symptom at baseline, the proportion experiencing symptom resolution was compared between groups using Pearson’s chi-square tests. Because not all patients with symptoms
experienced resolution of symptoms, Kaplan-Meier curves were generated and used to compare the time to first symptom resolution between groups. Among all study patients, for each symptom, the median time to first resolution for each group (that is, quetiapine versus placebo) was estimated from the Kaplan-Meier curves and the Log-rank test was used to compare the curves between the two groups. For each patient the proportion of time that each symptom was present was calculated. Additionally, the percent time when patients were at an appropriate level of consciousness was determined by subtracting the sum of (agitation plus decreased level of consciousness) from 1. Because the distribution of these proportions tended to be skewed, a nonparametric Wilcoxon rank sum test was used to compare the distributions between the quetiapine and placebo groups and data were summarized as medians and interquartile ranges (25th to 75th percentiles).

Given these were exploratory analyses and the fact that the original trial was not designed or powered to find associations with individual symptoms, we selected an alpha of \( P \leq 0.10 \) as our threshold for concluding statistical significance. While this higher threshold is more likely to find between-group differences when none exist (1/10 chance) when compared to the 1/20 chance when \( P < 0.05 \) is used, it is also more likely to find a significant association when one does exist, reducing type II errors. No adjustments to \( P \)-values for multiple comparisons were made given the exploratory nature of this study and unadjusted \( P \)-values for every comparison done are presented in tables.

**Results**

Acceptable data for the analysis of ICDSC delirium symptoms during blinded study drug administration were available for 29 of the 36 patients enrolled in the parent pilot study which required a diagnosis of delirium (quetiapine; \( n = 14 \); placebo; \( n = 15 \)). The information on the first seven patients enrolled at one of the study sites included only the ICDSC total score and the detailed individual symptoms were not available for this post-hoc analysis. All 29 other patients had at least 50% complete symptom data recorded and were included in this retrospective study. Overall, 16% of all possible ICDSC symptom data-points were not able to be assessed. Excessive sedation and inattention were the most common reasons for not assessing all ICDSC symptoms during the ICDSC assessments included in the analysis. Baseline age, gender, Acute Physiology and Chronic Health Evaluation (APACHE) II score and proportion of patients intubated were similar between each post-hoc group and the similar group in the parent study. At baseline, neither the ICDSC score (5 (4 to 6) (quetiapine) versus 5 (4 to 6); \( P = 0.32 \)) nor the incidence of each delirium symptom was different between the two groups (Table 1).

Among patients with the delirium symptom at baseline, use of quetiapine may lead to a shorter time to first resolution of symptom fluctuation (4 (quetiapine) vs. 14 days, \( P = 0.004 \)), inattention (3 vs. 8 days, \( P = 0.10 \)) and disorientation (2 vs.10 days, \( P = 0.10 \)), but a longer time to resolution of agitation (3 (quetiapine) vs. 1 days, \( P = 0.04 \)) and hyperactivity (5 vs. 1 days, \( P < 0.04 \)) (Table 2). Among all patients, quetiapine-treated patients tended to spend less percentage of time with inattention (47 (0 to 67) vs. 78 (43 to 100), \( P = 0.025 \)), hallucinations (0 (0 to 17) vs. 28 (0 to 43), \( P = 0.10 \)) and symptom fluctuation (47 (19 to 67) vs. 89 (33 to 100), \( P = 0.04 \)) and there was a trend for quetiapine-treated patients to spend more percentage of time at an appropriate level of consciousness (26 (13 to 63) vs. 14 (0 to 33), \( P = 0.17 \)) (Table 3).

**Discussion**

Recent investigations in both ICU and non-ICU populations have expanded the classification of patients with delirium from a dichotomous clinical diagnosis of delirium (that is, delirium or not), and focused instead on specific components of delirium, recognizing the heterogeneity of patients with this complex syndrome [15,16]. Recent data highlights the importance that individual symptom recognition and monitoring can have when managing delirium [33]. Individual delirium symptoms can be screened in ICU patients using a tool such as the ICDSC. Each delirium symptom evaluated with the ICDSC is highly discriminatory when distinguishing between critically ill patients with or without delirium, and after adjustment for severity of illness and coma, specific symptoms of delirium independently predict mortality in sub-syndromal delirium [26].

| Delirium symptoms evaluated by the ICDSC at study baseline | Quetiapine (\( n = 14 \)) | Placebo (\( n = 15 \)) | \( P \)-value |
|-----------------------------------------------------------|---------------------------|------------------------|---------------|
| Agitation                                                 | 5 (35.7)                  | 6 (40.0)               | 0.81          |
| Decreased level of consciousness                         | 6 (42.9)                  | 6 (40.0)               | 0.88          |
| Inattention                                               | 13 (92.9)                 | 15 (100.0)             | 0.29          |
| Disorientation                                            | 13 (92.9)                 | 11 (84.6)              | 0.49          |
| Hallucinations/Delusions                                  | 2 (14.3)                  | 1 (6.7)                | 1.00          |
| Hyperactivity                                             | 5 (35.7)                  | 6 (40.0)               | 0.81          |
| Hypoactivity                                              | 9 (64.3)                  | 9 (60.0)               | 0.81          |
| Inappropriate speech or mood                              | 7 (77.8)                  | 3 (42.9)               | 0.15          |
| Sleep/wake cycle disturbances                             | 8 (66.7)                  | 10 (71.4)              | 0.79          |
| Symptom fluctuation                                       | 11 (91.7)                 | 13 (86.7)              | 0.68          |

ICDSC, Intensive Care Delirium Screening Checklist
Our analysis is the first to measure the response of individual delirium symptoms to antipsychotic therapy in the ICU and suggests that quetiapine use is associated with more rapid resolution of many common ICU delirium symptoms when compared to a placebo, resulting in less time affected by hallucinations, inattention, symptom fluctuation and potentially less time at an undesirable level of consciousness. Although time to first resolution of agitation and hyperactivity was longer in patients receiving quetiapine, there appeared to be more time spent in a state other than agitation or psychomotor slowing, suggesting greater “normalcy” and symptom control. It remains unclear. However, with agitation and hyperactivity providing clinicians with the greatest challenge when caring for a patient with delirium and likely leading to the administration of additional sedatives or antipsychotic medications further research is needed to carefully evaluate this potential effect. While the relative sedating effects of haloperidol versus quetiapine are not well quantified, if haloperidol has the greater sedative effect, the fact that nearly twice as much “as needed” haloperidol was administered on average to the placebo group may also account for the faster resolution of agitation in this group. Identifying which symptoms are most important regarding long-term outcomes, and how best to describe their presence or absence, will require further study. Despite the well-established sedating properties of quetiapine, sleep-wake cycle abnormalities were not improved in this small sample of patients, suggesting sleep abnormalities

### Table 2 Proportion of patients experiencing resolution and time to first resolution for the delirium symptoms

| Delirium symptoms derived from ICDSC | Quetiapine (n = 14) | Placebo (n = 15) | P-value | Quetiapine (n = 14) | Placebo (n = 15) | C-P-value |
|--------------------------------------|--------------------|-----------------|---------|--------------------|-----------------|-----------|
| Agitation                            | 5 (100)            | 6 (100)         | -       | 84 (48 to 204)     | 36 (24 to 60)   | 0.07      |
| Decreased level of consciousness    | 5 (83.3)           | 6 (100)         | 0.30    | 36 (24 to 72)      | 24 (12 to 98)   | 0.78      |
| Inattention                          | 12 (92.3)          | 11 (73.3)       | 0.19    | 84 (24 to 168)     | 180 (72 to 240) | 0.12      |
| Disorientation                       | 11 (85.6)          | 8 (72.7)        | 0.47    | 48 (12 to 216)     | 204 (36 to 240) | 0.10      |
| Hallucinations/delusions             | 2 (100)            | 1 (100)         | -       | 48 (24 to 72)      | 156 (144 to 156)| 0.22      |
| Hyperactivity                        | 5 (100)            | 6 (100)         | -       | 120 (60 to 192)    | 24 (12 to 48)   | 0.04      |
| Hypoactivity                         | 7 (77.8)           | 6 (66.7)        | 0.60    | 72 (48 to 132)     | 168 (96 to 156) | 0.17      |
| Inappropriate speech or mood         | 6 (85.7)           | 3 (100)         | 0.49    | 132 (60 to 192)    | 72 (24 to 168)  | 0.31      |
| Sleep/wake cycle disturbance         | 5 (62.5)           | 6 (60.0)        | 0.91    | 48 (24 to 132)     | 228 (144 to 240)| 0.36      |
| Symptom fluctuation                  | 11 (91.7)          | 14 (93.3)       | 0.009   | 4 (1 to 10)        | 14 (7 to ne)    | 0.004     |

ICDSC, Intensive Care Delirium Screening Checklist

### Table 3 Time spent with each delirium symptom as a proportion of time study drug was administered

| Delirium symptoms derived from ICDSC | Quetiapine (Over course of study drug; N (%) | Placebo (Over course of study drug; N (%)) | P-value | Quetiapine (Time spent with delirium symptom (% of total days of study drug; median (IQR)) | Placebo (Time spent with delirium symptom (% of total days of study drug; median (IQR)) | C-P-value |
|--------------------------------------|---------------------------------------------|--------------------------------------------|---------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------|
| Agitation                            | 6 (42.9)                                    | 7 (46.7)                                   | 0.83    | 0 (0 to 13)                                                                    | 14 (0 to 57)                                                                     | 0.17      |
| Decreased level of consciousness     | 8 (57.1)                                    | 7 (46.7)                                   | 0.72    | 3 (0 to 50)                                                                    | 22 (7 to 29)                                                                     | 0.24      |
| Inattention                          | 13 (92.9)                                   | 15 (100)                                   | 0.29    | 47 (0 to 67)                                                                   | 78 (43 to 100)                                                                   | 0.03      |
| Disorientation                       | 13 (92.9)                                   | 12 (80)                                    | 0.59    | 35 (0 to 55)                                                                   | 52 (25 to 94)                                                                   | 0.27      |
| Hallucinations/delusions             | 2 (14.3)                                    | 1 (6.7)                                    | 1.00    | 0 (0 to 17)                                                                    | 28 (0 to 43)                                                                     | 0.10      |
| Hyperactivity                        | 6 (42.9)                                    | 7 (46.7)                                   | 0.79    | 0 (0 to 20)                                                                    | 14 (0 to 57)                                                                     | 0.28      |
| Hypoactivity                         | 9 (64.3)                                    | 9 (60.0)                                   | 0.81    | 50 (17 to 83)                                                                  | 67 (22 to 88)                                                                    | 0.61      |
| Inappropriate speech or mood         | 7 (77.8)                                    | 4 (16.0)                                   | 0.24    | 15 (0 to 44)                                                                   | 24 (0 to 60)                                                                     | 0.98      |
| Sleep/wake cycle disturbances        | 9 (64.3)                                    | 10 (71.4)                                  | 0.82    | 58 (33 to 100)                                                                 | 83 (36 to 100)                                                                   | 0.69      |
| Symptom fluctuation                  | 11 (91.7)                                   | 14 (93.3)                                  | 0.52    | 47 (19 to 67)                                                                  | 89 (33 to 100)                                                                   | 0.04      |

ICDSC, Intensive Care Delirium Screening Checklist

*Among all patients and, therefore, regardless of whether each delirium symptom was present at baseline.

*Time spent was based on the number of 12 hour shifts where the symptom was present

*For comparison of distributions between the two groups for time spent with delirium symptom using the Wilcoxon rank sums test
associated with delirium may not be palliated with quetiapine.

Few other reports of quetiapine use for delirium have been published, and none were ICU-based studies. A recent, randomized, double-blind study compared delirium resolution with quetiapine or placebo treatment among hospitalized (but not ICU) medical and surgical patients and found the cognitive components recovered 83% faster in the quetiapine group, and noncognitive scores recovered 57% faster than the placebo group [33].

A number of limitations of our study must be considered. First, patients were enrolled in the parent randomized controlled study an average of six days after ICU admission - nearly twice as long after ICU admission as when delirium often first presents [14]. Study enrollment may have been delayed by our requirement that delirium be an established diagnosis and treatment with haloperidol initiated prior to consent and randomization and that adequate gut function (for example, tolerating enteral nutrition) be established. Although not well characterized, it is possible that the individual symptoms of delirium present in a patient with delirium vary with time after ICU admission [26]. Second, while a summary ICSD score was documented for all study patients, documentation of individual delirium symptoms (from the ICSDC) was missing for 7 of the 36 patients in the parent study. It is possible that the results of this secondary analysis may have been different had all 36 patients been included although baseline demographics and the time to first resolution of delirium were similar between each post-hoc group (n = 14, n = 15) and the corresponding groups in the parent study (n = 18, n = 18). Some of the delirium symptoms (for example, hallucinations) may have been detected at too low of a frequency to allow for a valid analysis of their time to resolution between the two study groups.

We provide clinical information regarding the short-term response of ICU symptoms, but did not evaluate long-term follow-up after hospital discharge for these patients. Whether long-term cognitive function may be related to specific symptoms identified during the ICU stay (as it is with delirium in general) remains unknown. Since the study was initiated only in delirious patients, the effect psychotropic drugs may have on subsyndromal delirium remains unexplored. With multiple comparisons of 10 symptoms that were tested and the small sample size, we chose to look for promising differences which may serve as a foundation for future studies powered for this type of analysis. We also present the individual unadjusted P-values for every comparison made, in the spirit of maximal transparency and to fuel future studies in this area.

Conclusions

Our exploratory analysis suggests that quetiapine appears to resolve many ICU delirium symptoms faster than the placebo, may result in less time with hallucinations, inattention and symptom fluctuation and may allow patients to spend more time at a desirable level of consciousness. Future studies evaluating pharmacologic therapy for ICU patients with delirium or subsyndromal delirium may benefit from monitoring the resolution and duration of individual delirium symptoms and long-term cognitive function to determine whether the different psychiatric symptoms of delirium are associated with worse or better outcomes.

Key messages

- This study, the first to measure the response of individual delirium symptoms to antipsychotic therapy in the ICU, demonstrates that quetiapine use may be associated with more rapid resolution of many common ICU delirium symptoms compared to placebo, resulting in less time affected by hallucinations, inattention, symptom fluctuation and an undesirable level of consciousness.
- Psychomotor agitation and hyperactivity, a potential marker for lower mortality among delirious patients but predictive of worse outcome among patients not delirious, took longer to resolve with quetiapine in this pilot study, but quetiapine appears to lead to more time without agitation or depressed consciousness.
- Future studies evaluating antipsychotics in ICU patients with delirium should measure the resolution of individual delirium symptoms.

Abbreviations

APACHE II: Acute Physiology and Chronic Health Evaluation II; DSM: diagnostic and statistical manual; ICSDC: intensive care delirium screening checklist; ICU: intensive care unit; IQR: interquartile range.

Author details

1Northeastern University School of Pharmacy, 360 Huntington Avenue, Mugar 206, Boston, MA 02115, USA. 2Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA. 3Department of Critical Care Medicine, Maisonneuve-Rosemont Hospital, 5415 de l’Assomption, Montreal, QC H1T 2M4, Canada. 4Department of Critical Care Medicine, Maine Medical Center, 22 Bramhall Street, Portland, ME, 04102, USA. 5Department of Pharmacy, Tufts Medical Center, 800 Washington Street, mailstop #420, Boston, MA 02111, USA. 6Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, 19 Foster Street, Worcester, MA 01608, USA. 7Institute for Clinical Research and Health Policy Studies, Biostatics Research Center Tufts Medical Center, 35 Kneeland Street, Boston, MA 02111, USA.

Authors’ contributions

JWD was responsible for the concept, acquisition and interpretation of data, manuscript preparation, and final manuscript approval. VS, RRR, NH and EH were responsible for the acquisition and interpretation of data, manuscript preparation, and final manuscript approval. RR, RJR, JIF and EG were
responsible for the interpretation of data, manuscript preparation, and final manuscript approval.

Competing interests
The authors declare that they have no competing interests. None of the authors have conflicts of interest surrounding this study.

This study was presented in part at the 40th Annual Congress of the Society of Critical Care Medicine, January, 2011.

Received: 29 June 2011 Revised: 31 July 2011
Accepted: 17 September 2011 Published: 17 September 2011

References
1. Skrobik Y. Delirium prevention and treatment. Crit Care Clin 2009, 25:585-91.
2. Oumet S, Kavanagh BP, Gottfried SB, Skrobik Y. Incidence, risk factors and consequences of ICU delirium. Intensive Care Med 2007, 33:66-73.
3. Ely EW, Gautam S, Margolin R, Francis J, May L, Speroff T, Truman B, Dittus R, Bernard R, Inouye SK. The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med 2001, 27:1892-1900.
4. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr,捆绑 L, Bernard GR, Dittus RS. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004, 291:1753-1762.
5. Shehabi Y, Riker RR, Bokesch PM, Wisemandle W, Shintani A, Ely EW. Delirium duration and mortality in lightly sedated, mechanically ventilated intensive care unit patients. Crit Care Med 2010, 38:2311-2318.
6. Pinion MA, Kongo SY, Kasl SV, Murphy TE, Araujo KL, Van Ness PH. Days of delirium are associated with 1-year mortality in an older intensive care unit population. Am J Respir Crit Care Med 2008, 180:1092-1097.
7. Girard TD, Jackson JC, Pandharipande PP, Bun PT, Thompson JL, Shintani AK, Gordon SM, Canonico AE, Dittus RS, Bernard GR, Ely EW. Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Crit Care Med 2010, 38:1513-1520.
8. Bergner N, Dubois MJ, Dumont M, Dal S, Skrobik Y. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med 2001, 27:859-864.
9. Neufeld KD, Hayat MJ, Coughlin HM, Huberman AL, Leistkov NA, Krumm SK, Needham DM. Evaluation of two intensive care delirium screening tools for non-critically ill hospitalized patients. Psychosomatics 2011, 52:133-140.
10. Luettz A, Heymann A, Radtke FM, Chenitt C, Neuhaus U, Nachtigall I, von Dossow V, Marsz S, Eggers V, Heinz A, Wernecke KD, Spies CD. Different assessment tools for intensive care unit delirium: Which score to use? Crit Care Med 2010, 38:409-418.
11. Devlin JW, Fong J, Schumaker G, O’Connor H, Ruthazer R, Garpestad E. Use of a validated delirium assessment tool improves the ability of physicians to identify delirium in medical intensive care unit patients. Crit Care Med 2007, 35:2721-2724.
12. Devlin JW, Marquis F, Riker RR, Robbins T, Garpestad E, Fong JJ, O’Connor H, Ruthazer R, Garpestad E, Fong JJ, Didomenico D, Skrobik Y. Combined didactic and scenario-based education improves the ability of intensive care unit staff to recognize delirium at the bedside. Crit Care 2008, 12:R19.
13. Skrobik Y, Devlin JW. The intensive care delirium screening checklist has many potential benefits over the nursing delirium screening scale. Crit Care Med 2010, 38:1610-1611, author reply 1611-1612.
14. Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, Speroff T, Gautam S, Bernard GR, Inouye SK. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med 2001, 29:1370-1379.
15. Oumet S, Riker R, Bergner N, Cossette M, Kavanagh B, Skrobik Y. Subsyndromal delirium in the ICU: evidence for a disease spectrum. Intensive Care Med 2007, 33:1007-1013.
16. Cole M, McCusker J, Dendukuri N, Han L. The prognostic significance of subsyndromal delirium in elderly medical inpatients. J Am Geriatr Soc 2003, 51:754-760.
17. Meagher D, Treszpacz PT. Phenomenological distinctions needed in DSM-V: Delirium, subsyndromal delirium and dementias. J Neuropsychiatry Clin Neurosci 2007, 19:468-470.